• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, Nov. 25

The Maharashtra FDA has asked pharmaceutical major Wockhardt Ltd to withhold sales and withdraw Wosulin 50-50 injection vials (insulin) after

carrying out investigations on a sample of the drug manufactured at the Aurangabad factory. The vials have been distributed in Maharashtra, Andhra Pradesh, Tamil Nadu and Delhi. A sample of the drug has been sent to the Central Research Institute, Kasauli, for analysis. "We have received some reports about the quality of Wosulin vials and we are investigating the same. Prima facie it appears to be due to improper temperature during transit. Meanwhile, we are withdrawing the stocks as directed by Maharashtra FDA," said a company spokesperson.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Vijay Shanti projects on hand worth Rs 750 cr

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line